(TXG) 10x Genomics, Inc. Business Model Canvas Research

Biopharma and biotech collaborators use 10x Genomics, Inc. tools for target discovery, biomarker work, and cell-state analysis, so joint assay design stays close to real R&D needs. These projects often turn into repeat consumable use, which supports a recurring revenue base: in FY2025, consumables remained the main demand driver across the platform.

• Target discovery and biomarker work
• Assay design shaped with R&D teams
• Repeat consumable use from joint projects

10x Genomics uses global distributors and channel partners to serve customers across North America, Europe, the Middle East, Africa, China, and Asia Pacific. In 2025, its revenue came from a broad global base, and local partners handle ordering, logistics, and market access in countries where direct coverage would be less efficient.

• Expands reach across six regions
• Supports local ordering and delivery
• Improves coverage in hard-to-serve markets

10x Genomics’ software turns sequencing output into usable biology, and that matters because it supports the company’s $651.6 million in 2024 revenue by keeping researchers inside the workflow. The tools for processing, visualization, and interpretation also make switching harder, which helps retention and repeat use.

• Data processing to biological insight
• Supports workflow stickiness
• Helps drive repeat use and retention

10x Genomics, Inc. relies on application scientists to help customers design experiments and fix workflow issues in its multi-step sequencing and spatial assays. That hands-on support matters because a failed run can waste costly consumables and delay data, so training and troubleshooting help protect customer value and repeat use.

• Designs experiments and workflows
• Troubleshoots complex assay steps
• Trains users to cut failed runs
• Builds stickier long-term customer ties

Scientific and engineering talent is 10x Genomics, Inc.'s main key resource: biologists, chemists, engineers, and software developers build new assays, instruments, and analysis tools. In FY2024, revenue was about $610.7M, and that pace depends on how fast this team turns research into launch-ready products.

• Drives assay innovation
• Shapes instrument design
• Improves software analysis
• Speeds product launches

10x Genomics, Inc.’s global sales, service, and applications network is a key resource because it helps labs adopt Chromium and Visium systems in both academic and biopharma settings. The same field teams keep instruments running and drive consumable use, which matters because 2025 revenue was still tied mainly to installed-base activity and repeat reagent demand.

• Supports adoption across regions
• Keeps instruments online
• Drives consumable repeat use

10x Genomics' Chromium platform can process tens of thousands of cells in one run, with Chromium X scaling to 100,000 cells per sample, so teams can handle discovery studies and large cohorts without building custom workflows. That gives higher throughput and faster turnaround with less setup friction.

• Up to 100,000 cells per run

• Built for large sample sets

• Less custom workflow work

10x Genomics sells instruments, consumables, and software as one linked system, which cuts setup steps and helps users get more reproducible results. Its bundled model also speeds time to data; in 2024, the Company reported $651.5 million in revenue, showing the scale of this standardized workflow.

• One system, less setup friction
• Better reproducibility across runs
• Faster path from sample to data

Repeat consumable replenishment keeps 10x Genomics, Inc. tied to customers after the first instrument sale: once a lab installs a system, it must keep buying reagents, chips, and slides to run new experiments. That recurring demand improves retention and makes revenue easier to forecast as the installed base grows.

In fiscal 2025, this model still mattered because consumables are the follow-on spend that drives repeat orders after each instrument placement.

• Reagents, chips, and slides repeat
• Installed base drives reorder flow
• Recurring sales improve revenue visibility

10x Genomics, Inc. builds scientific ties through conferences, posters, publications, and user communities. In life sciences, peer-reviewed validation is key, so this engagement helps signal product performance and builds trust with researchers who need reproducible results.

• Conferences and posters drive discovery.
• Publications support peer review.
• User communities reinforce adoption.

Scientific conferences and webinars are key discovery channels for 10x Genomics, Inc.; they let the Company show new assays and share validated data, which matters in credibility-led buying. In 2025, this matters even more because life-science buyers want proof before switching platforms.

• Show new assays fast
• Use data to build trust
• Support higher-value purchases

Peer-reviewed publications and application notes help 10x Genomics, Inc. shape demand in academic and translational research, where published validation often drives purchase choices. This channel also lowers first-use risk by showing workflow performance and best practices, which matters in a market where 2025 R&D spend was still a major buyer filter for labs.

• Published data supports buying decisions
• Application notes show real workflow results
• Reduces uncertainty for new users

For 10x Genomics, Inc., this content works as proof, training, and sales support in one.

Biotechnology companies use 10x Genomics for assay development, disease biology, and platform programs, and they often switch between product families as projects move from discovery to scale. In 2025, this matters because the workflow mix spans Chromium, Visium, and Xenium, so fast turnaround and flexible protocols are key buying drivers.

• Uses multiple product families over time
• Needs flexible, fast workflows
• Supports assay and disease research
• Fits platform program expansion

Core facilities, shared tech centers, and CROs are high-volume buyers for 10x Genomics, Inc. because they run samples for many users and need standard workflows, strong support, and repeatable throughput. Their utilization turns each instrument into recurring consumable demand, so one busy core can support dozens to hundreds of runs a year.

• Multi-user sample processing
• Standardized, repeatable workflows
• High-throughput, recurring consumables

General and administrative expenses cover 10x Genomics, Inc.'s finance, legal, HR, and IT teams, plus public-company compliance and global overhead. In FY2025, this cost line stayed tied to scaling across regions and product lines, so it matters for margin control as the business grows.

• Finance, legal, HR, and IT support core operations
• SEC compliance adds public-company cost
• Global overhead rises with scale

10x Genomics, Inc. depends on global warehousing and shipping for reagents and instruments, so logistics cost hits every order through freight, customs, and cold-chain handling. Many products are temperature sensitive, often requiring 2°C-8°C or frozen storage, which raises inventory planning risk and makes lot traceability and tight stock control essential.

Quality systems also carry real cost because 10x Genomics, Inc. must keep life-science products reproducible across labs and batches. That means validated processes, release testing, and complaint tracking, all of which reduce failure risk but add fixed overhead and slow scale if controls slip.

• Cold-chain shipping protects sensitive reagents.
• Inventory errors can cause write-offs.
• Quality control supports reproducible results.

10x Genomics, Inc. earns software and analysis revenue by selling data tools and informatics support that sit after sequencing and help customers interpret complex single-cell and spatial datasets. In 2025, that layer stayed strategic because software raises workflow value and helps keep customers inside the 10x Genomics ecosystem.

• Supports post-sequencing analysis
• Improves workflow value
• Helps retain customers
• Handles complex single-cell data
• Handles complex spatial data

Service, support, and replacement parts add recurring revenue for 10x Genomics, Inc. by keeping Chromium and Visium systems running well after the initial sale. This matters because the company’s large installed base turns technical support and spare parts into steady, higher-margin follow-on sales.

• Boosts recurring, post-sale revenue
• Keeps instruments performing well
• Supports customer retention over time